Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
Winai Porntipworawech, Former Vice President of GCME shared a post on LinkedIn:
“Brazilian scientists at Butantan Institute developed a snake venom-derived drug that dissolves dangerous blood clots within minutes without major side effects.
The medication costs $50 per treatment compared to American alternatives charging more than $5,000 with significant bleeding risks.
The drug uses a modified protein from Brazilian pit viper venom that specifically targets clot-forming proteins.
Unlike American blood thinners that affect entire clotting systems, this medication only dissolves existing dangerous clots.
Patients avoid the bleeding complications that kill thousands yearly from traditional treatments.
It works like targeted demolition rather than carpet bombing.
The pharmaceutical industry resistance reveals priorities.
American drug companies promote expensive blood thinners despite high complication rates and limited effectiveness.
The cheap Brazilian alternative threatens $30 billion in yearly American anticoagulant sales.
Critics argue industry lobbying delays FDA approval despite proven safety in extensive Brazilian trials.
For 795,000 Americans suffering strokes yearly and millions taking blood thinners, this represents lifesaving innovation kept inaccessible.
The current American treatment causes 1 in 100 patients to suffer dangerous bleeding episodes.
Brazilian alternatives prevent both clots and complications while costing 100 times less than American medications.
Should American patients suffer dangerous side effects when Brazilian alternatives prove safer and cheaper?
Source: Butantan Institute and New England Journal of Medicine, February 2025″
Stay updated with Hemostasis Today.
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall
-
Jun 10, 2026, 17:51Mariam Swidan: Some Red Blood Cells Can’t Handle Pressure
-
Jun 10, 2026, 17:49Ankit Mathur: Hosting ISBT Academy Day on Rare Donor Program in India
-
Jun 10, 2026, 17:48Shadi Tabibian: When Patients Bleed but Standard Testing Is Normal
-
Jun 10, 2026, 17:47Mervyn Morgan: Discussing Current ITP Research at Imperial College London